(More on government funded inventions here) 2015 2015: Virotas Biopharmaceuticals. KEI and Public Citizen ask NIH for safeguards in license for HCV patents, April 14, 2015. 2015: NIH refuses to give information about principals in company seeking exclusive license to… Continue Reading
The World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.8 on Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018 the either… Continue Reading
KEI has submitted an amicus brief in support of Respondents in the case of Oil States Energy Services, LLC, v. Greene’s Energy Group, LLC, currently before the Supreme Court. The brief is attached here.
On Wednesday, 4 October 2017, Knowledge Ecology International (KEI) delivered the following statement at the WIPO General Assembly during discussions on the Report of the Standing Committee on the Law of Patents (SCP).
WIPO General Assembly 2017 – Statement of KEI on the Report on the Standing Committee on the Law of Patents (SCP)
4 October 2017
Agenda item: 14. Report on the Standing Committee on the Law of Patents (SCP)
Kite Pharma is a California-based biopharmaceutical company working on various types of cell therapies for the treatment of cancer, in a bid to become the first pharmaceutical firm to gain successful FDA approval for this new class of cancer treatment.
Kite closely collaborates with the National Cancer Institute, which conducted significant early research into the forms of cell therapies that Kite is seeking to commercialize. NCI conducts clinical trials under Cooperative Research and Development Agreements (CRADAs) with Kite, and additionally has granted exclusive licenses on over a dozen patents to Kite on the same technologies.
Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On May 18th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dimension… Continue Reading
On Thursday, 23 January 2014, the South Centre delivered the following statement at the 134th session of the World Health Organization’s Executive Board under agenda item 9.7, access to essential medicines, expressing solidarity with the Government of the Republic of South Africa following the Pharmagate exposé.
GRACIAS SENORA PRESIDENTA POR DARNOS LA PALABRA.News reports and blogs on innovation prizes
Return to KEI page on prizes to stimulate innovation
A separate page on academic and other technical papers and comments on prizes is available
here:
News Reports and Blogs on Innovation Prizes
KEI Comments on Exclusive License of Zika Strain to AARI
On October 14, 2025, Knowledge Ecology International (KEI) provided the NIH with comments regarding the “Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Development of Zika Virus Strains for Use in Oncolytic Therapy” (90 FR 46414) to Advocate Aurora Research… Continue Reading
WHO IGWG3 – KEI’s statement at opening, focuses on transparency, technology transfer and pricing of products, WHO pathogen access and benefit sharing system (PABS) negotiations
On Monday, 3 November 2025, Knowledge Ecology International (KEI) delivered the following intervention at the Third meeting of the open-ended Intergovernmental Working Group on the WHO Pandemic Agreement. Given the significant attacks on the WHO and the importance of restoring… Continue Reading